

On the Occasion of the World Hepatitis Day: World Hepatitis Day and Our Achievements and Responsibilities in Iran

Seyed Moayed Alavian

Director of Iran Hepatitis Network,
Baqiyatallah Research Center for
Gastroenterology and Liver Diseases,
Ground floor of Baqiyatallah
Hospital, Mollasadra Ave., Vanak Sq.
P.O.Box 14155-3651, Tehran, Iran

Date of Submission: May 21, 2012

Date of Acceptance: June 10, 2012

Correspondence to:

Prof. Seyed Moayed Alavian,
Director of Iran Hepatitis Network,
Baqiyatallah Research Center for
Gastroenterology and Liver Diseases,
Ground floor of Baqiyatallah
Hospital, Mollasadra Ave., Vanak
Sq. P.O.Box 14155-3651, Tehran, Iran.
E-mail: alavian@thc.ir

How to cite this article: Alavian SM. On the occasion of the world hepatitis day: World hepatitis day and our achievements and responsibilities in Iran. *Int J Prev Med* 2012;3:437-9.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the major causes of liver disease worldwide and the health policy makers with their strategies try to control these infections in the communities.^[1-5] HBV infection is the main cause of chronic liver disease in Iran,^[6] but fortunately prevalence has decreased dramatically in the Iranian population during last decade^[6] and the endemicity of infection is changing from intermediate to low in Iran.^[7] Improvement of the people's knowledge about HBV risk factors, national vaccination program since 1993 for all neonates, vaccination of adolescence, and vaccination of high risk groups could be the cause of this decrease.^[8,9] Ministry of Health in Iran is serious about controlling hepatitis B. Coverage rate more than 97% of infants, expansion of vaccination to more age in adolescent period, vaccination of health-care workers, and family of HBs Ag positive free of charge are the main strategies in Iran.^[10] But we need to more evaluation of risk factors in HBV-infected people for designing the strategies to control the disease in future. Higher prevalence of HBV infection in some parts of Iran such as Golestan province needs more attention.^[11]

HCV is an emerging disease worldwide and will be a potential source of substantial cases

of morbidity and mortality in the future.^[12] It is estimated that approximately 170 million individuals, i.e., 3% of the world's population, are chronically infected with the HCV.^[13] The prevalence varies markedly from one geographical area to another and within the population assessed.^[7] Iran is a low prevalence of HCV infection and the estimation in the general population shows that it is less than 0.5%.^[4,14] The epidemiological patterns of HCV vary greatly among the different countries and even among the regions of the same country. The epidemiology varies geographically and temporally due to its distribution and the evolution of risk factors.^[15] Studying the epidemiology and risk factors of HCV infection plays an important role in the methods of its prevention. Injection drug users (IDUs) are the main risk factors for acquiring of HCV infection in our community.^[16] In addition to drug use, most drug abusers experience high-risk behaviors such as unsafe sexual activities, tattooing, unsafe injections, and cocaine use resulting in high prevalence rates in the IDUs group in our country.^[17] A range of prevention measures for IDUs has been implemented including syringe exchange programs, syringe vending machines, increased outreach efforts, and access to methadone maintenance treatment (MMT).^[18] In Iran, the

harm reduction program has been accepted by the high level authorities in the government and we adapted it to our religious and traditional culture and it is very effective plan in control of HCV infection in this high-risk group.^[18,19] It seems that HCV infection is more concentrate in hemodialysis, hemophilia, and thalassemia patients in Iran and fortunately during recent years the burden of infection has decreased significantly in these groups.^[2,3,20] Screening of all thalassemia and hemophilia patients for HCV infection in all provinces in Iran and providing the free of charge of antiviral drugs was the best strategy for control of HCV infection in this high-risk group.^[21-23] With implementation of mandatory HCV screening of blood and blood products in the 1995 in Iran, the number of posttransfusion infections had already decreased dramatically in special patients.^[24] The epidemiological patterns of HCV vary greatly among the different countries and even among the regions of the same country.^[25,26]

World Hepatitis Day (28 July) is an annual event that has marked to increase the awareness and understanding of viral hepatitis and the diseases that it causes. July 28th is the birthday of Dr. Baruch Blumberg. Dr. Blumberg discovered the hepatitis B virus in 1967 and 2 years later developed the first hepatitis B vaccine and for these achievements won the Nobel Prize. The first World Hepatitis Day launched by World Hepatitis Alliance in 2008. Following the World Health Assembly in May 2010, it was agreed that World Hepatitis Day would be recognized annually on 28 July. It is an opportunity around the world for raising the people and health policy makers for more knowledge sharing and better approach for control of HBV and HCV infections in their communities. The role of media with collaborations of gastroenterology and hepatology and infectious centers for generation massive public informative and educational materials is very critical. This annual event should provide more sense for collaboration in the communities. The governments will focus on strengthening prevention, screening and control of viral hepatitis with increasing hepatitis B vaccine coverage and integration of viral hepatitis in surveillance system, and coordinating a national response to viral hepatitis in the country. Increasing the access to new tests and therapy for all infected people in the

country is another important strategy for control of viral hepatitis in the country.

REFERENCES

1. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. *Iran J Clin Infect Dis* 2010;5:51-61.
2. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. *Gastro Hepat FBB* 2010;3:5-14.
3. Alavian SM, Fallahian F. Epidemiology of Hepatitis C in Iran and the World. *Shiraz E-Med J* 2009;10:162-72.
4. Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. *Hepat Mon* 2009;9:211-23.
5. Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. *Hepat Mon* 2008;8:281-94.
6. Alavian SM, Fallahian F, Bagheri-Lankarani K. The Changing Epidemiology of Viral Hepatitis B in Iran. *J Gastrointestin Liver Dis* 2007;16:403-6.
7. Alavian SM. New globally faces of hepatitis B and C in the world. *Gastro Hepat FBB* 2011;4:171-4.
8. Alavian SM. Immunization: An Important Strategy to Control Hepatitis B. *Hepat Mon* 2006;6:3-5.
9. Alavian SM, Gooya MM, Hajarizadeh B, Esteghamati AR, Moeinzadeh AM, Haghazali M, *et al.* Mass Vaccination Campaign against Hepatitis B in Adolescents in Iran: Estimating Coverage using Administrative Data. *Hepat Mon* 2009;9:189-95.
10. Alavian SM. Ministry of Health in Iran Is Serious about Controlling Hepatitis B. *Hepat Mon* 2007;7:3-5.
11. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, *et al.* The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: A population-based study. *Arch Iran Med* 2009;12:225-31.
12. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. *Arch Iran Med* 2005;8:84-90.
13. Marcellin P. Hepatitis B and hepatitis C in 2009. *Liver Int* 2009;29 Suppl 1:1-8.
14. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, *et al.* Seroprevalence of hepatitis C virus: The first population-based study from Iran. *Int J Infect Dis* 2010;14 Suppl 3:e113-6.
15. Yan Z, Fan K, Wang Y, Fan Y, Tan Z, Deng G. Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. *Hepat Mon* 2012;12:196-204.
16. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk

- factors in Iranian volunteer blood donors: A case-control study. *J Gastroenterol Hepatol* 2002;17:1092-7.
17. Alavian SM. We Need a New National Approach to Control Hepatitis C: It is Becoming too Late. *Hepat Mon* 2008;8:1-3.
 18. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, *et al.* Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. *Int J Drug Policy* 2007;18:359-63.
 19. Alavian SM. Control of Hepatitis C in Iran: Vision and Missions. *Hepat Mon* 2007;7:57-558.
 20. Kabir A, Alavian SM, Lankarani KB. Epidemiology of HCV Infection among Thalassemia Patients in Eastern Mediterranean Countries: Some Comments-reply. *Iran Red Cres Med J* 2011;13:1-2.
 21. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, *et al.* Low Dose Ribavirin for Treatment of HCV Infected Thalassemia Major Patients; New Indications for Combination Therapy. *Hepat Mon* 2012;12:In Press.
 22. Alavian SM, Aalaei-Andabili SH. Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis. *Hepat Mon* 2012;12:244-52.
 23. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, *et al.* Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: A single-centre study of 367 cases. *Liver Int* 2010;30:1173-80.
 24. Cheraghali AM. Blood safety concerns in the Eastern Mediterranean region. *Hepat Mon* 2011;11:422-6.
 25. Alavian SM, Aalaei-Andabili SH. More Risk Factors of Hepatitis C Transmission Should be Considered in Pakistan. *Int J Prev Med* 2011;2:188-9.
 26. Hashmi A, Saleem K, Soomro JA. Prevalence and Factors Associated with Hepatitis C Virus Seropositivity in Female Individuals in Islamabad, Pakistan. *Int J Prev Med* 2010;1:252-6.

Source of Support: Nil. **Conflict of Interest:** None declared.